secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001171843-25-003183
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2
--------------------------------------------------------------------------------

- Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.
- Completed $15M equity financing from institutional investors; cash and equivalents total $13.9M.
- EB06 Phase 2 IND submission to FDA expected H2 2025; topline results 12-18 months after clearance.
- EB05 ARDS study fully funded by government; R&D spend shifted from EB05 to EB06 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325003183/0001171843-25-003183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184325003183/f8k_051425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer